1244P Durvalumab after definitive radiochemotherapy (RCT) in locally advanced unresectable NSCLC: Real-world data on survival and safety from the German expanded access program (EAP)

Authors :: P. Schuett
F. Steger
M. Faehling
S. Eisenmann
M. Horn
S. Sackmann
Petra Hoffknecht
A. Schlenska-Lange
Petros Christopoulos
Daniel C. Christoph
S.P. Aries
Christian Schumann
Jürgen Alt
Source :: Annals of Oncology. 31:S806-S807
Publication Year :: 2020
Publisher :: Elsevier BV, 2020.

Subjects :: medicine.medical_specialty
Durvalumab
business.industry
Locally advanced
Hematology
language.human_language
law.invention
German
Oncology
Randomized controlled trial
law
Expanded access
language
Medicine
Medical physics
business
Real world data

Full Text Access

Tools